Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.

Cabanas M, Pistono C, Puygrenier L, Rakesh D, Jeantet Y, Garret M, Cho YH.

Neurotherapeutics. 2019 Mar 26. doi: 10.1007/s13311-019-00726-3. [Epub ahead of print]

PMID:
30915710
2.

Alterations in Hippocampal Inhibitory Synaptic Transmission in the R6/2 Mouse Model of Huntington's Disease.

Dargaei Z, Liang X, Serranilla M, Santos J, Woodin MA.

Neuroscience. 2019 Apr 15;404:130-140. doi: 10.1016/j.neuroscience.2019.02.007. Epub 2019 Feb 22.

PMID:
30797895
3.

Ghrelin-mediated improvements in the metabolic phenotype in the R6/2 mouse model of Huntington's disease.

Rudenko O, Springer C, Skov LJ, Madsen AN, Hasholt L, Nørremølle A, Holst B.

J Neuroendocrinol. 2019 Feb 18:e12699. doi: 10.1111/jne.12699. [Epub ahead of print]

PMID:
30776164

Supplemental Content

Support Center